The Prolaris test can more accurately predict the aggressiveness of prostate cancer allowing for more precise treatment and avoidance of more intense therapies with a patient’s parallel morbidities.
Read More
The study validated the Decipher RP test as an independent predictor of distant metastases, prostate cancer-specific mortality, and overall survival.
Read More
Decipher’s comprehensive portfolio of tests in urologic cancers leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making.
Read More
The strategic partnership between Myriad and Illumina consists of a time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets.
Read More
The study data provides a potential new approach to early detection of prostate cancer and an alternative to invasive biopsies.
Read More